New Membership to Help Accelerate Adoption of Semantic Web Standards In Commercial Products for Life Sciences R&D
SEATTLE, Wash. -- June 6, 2005 -- Teranode Corporation, the leading innovator of experiment design automation (XDA) software for the Life Sciences industry, today announced its membership to the World Wide Consortium (W3C). W3C is an international consortium where member organizations, staff, and the public work together to develop Web standards and lead the WWW to its full potential by developing protocols and guidelines that ensure long-term growth for the Web. Specifically, Teranode's membership is intended to establish meaningful collaborations with the Semantic Web for Life Sciences working group and accelerate implementation of standards in TERANODE XDA.
"Semantic Web standards, in combination with commercial products like TERANODE XDA, are essential to breaking bottlenecks associated with data access and data flow in Life Sciences," said Joseph Duncan, CEO of Teranode Corporation. "TERANODE XDA is an informatics platform that accelerates the availability and improves the quality of experiment data. Integrating Semantic Web standards as part of our platform will further increase the accessibility and mobility of this critical data."
Model-driven Informatics: Infrastructure for the Semantic Web
Discovery is challenged by constantly changing data requirements, increasing analytics complexity, and growing network of collaborators. The Semantic Web helps organizations to overcome these challenges. Until recently, companies have had only two choices on which to implement a Semantic Web: relational schemas and documents. Relational schemas provide scalability at a cost of expensive development, limited flexibility, and poor data mobility. Documents provide flexibility and mobility but are error-prone, labor intensive, and not searchable. TERANODE XDA offers a third form of infrastructure based on models that provides the scalability and reliability of relational schemas with the flexibility and mobility of documents. TERANODE XDA enhanced with RDF and other Semantic Web standards provide a flexible, scalable, and reliable data infrastructure for a Semantic Web in life science organizations.
For more about model-driven informatics, please see the IDC Life Science Insights white paper entitled, "Experiment Design Automation: A Potential Solution for Fragmented Informatics in Biopharmaceutical Research and Development." You can register for this report by going to: www.teranode.com/modeldriven.
About the World Wide Web Consortium (W3C)
The W3C was created to lead the Web to its full potential by developing common protocols that promote its evolution and ensure its interoperability. It is an international industry consortium jointly run by the MIT Computer Science and Artificial Intelligence Laboratory (MIT CSAIL) in the USA, and the European Research Consortium for Informatics and Mathematics (ERCIM), headquartered in France and Keio University in Japan. Services provided by the Consortium include: a repository of information about the World Wide Web for developers and users, and various prototype and sample applications to demonstrate use of new technology. To date, over 360 organizations are members of the Consortium. For more information on W3C, go to: www.w3.org/.
About Teranode Corporation
Teranode Corporation, headquartered in Seattle, WA, is the leading innovator of experiment design automation (XDA) software to improve speed and quality of experimentation for the benefit of accelerated R&D. The company, founded in 2002 to revolutionize the role that computing plays in Life Sciences, began with technologies invented by the founders at the University of Washington. TERANODE XDA is being used by leading pharmaceutical, biotechnology, research, and academic organizations including Pfizer, AstraZeneca, and Fred Hutchinson Cancer Research Center.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.